ESR1 and breast cancer: Intriguingly, cyclin D1 positive breast cancers typically exhibit low proliferative rates, and dual positive immunostaining for ER and cyclin D1 expression has been associated with positive outcome and/or survival in some studies [67-70], suggesting that the ability of cyclin D1 to promote ER activity may enhance a differentiative phenotype.